Clinical Trial Update: A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 study update for orelabrutinib in relapsing-remitting multiple sclerosis is reported as ongoing with no published results yet.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Orelabrutinib (orelabrutinib)

Snippet

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. | Conditions: Relapsing Remitting Multiple Sclerosis | Phase 2 | Status: UNKNOWN